While ABT-199 (venetoclax) has demonstrated remarkable efficacy in CLL treatment (Lasica and Anderson, 2021), its therapeutic impact is often compromised by the overexpression of BCL-2 and other anti-apoptotic proteins such as MCL-1. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.